Overview

Update
Status
Acquired by on October 31, 2013
IPO / Stock
Went Public on Jun 28, 2011 / OTCBB:GNBP
Headquarters:
Los Angeles, CA
Description:
Genesis Biopharma develops immunotherapies based on patient-specific T-cells to treat metastatic melanoma and other solid cancers.
Categories:
Biotechnology
Website:
http://www.genesis-biopharma.com
Social:

Company Details

Update
Founded:
Unknown
Aliases:
Genesis Biopharma, Inc, Lion Biotechnologies, Inc.
Contact:
866-963-2220
Employees:
11 - 50 | 2 in Crunchbase

Genesis Biopharma, Inc. Merge with Lion Biotechnologies, Inc.

Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer.

Our lead product candidate, Cōntego™, is an autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is being developed as a ready-to-infuse autologous cell therapy product. Following resection of the patient’s tumor, TILs are isolated from the resected tumor, and expanded in vitro to several billion cells. The expanded TILs are then infused into the patient where they attack the melanoma tumors regardless of their location in the body.

Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma. Dr. Rosenberg’s adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.

Funding Rounds (5) - $7.74M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2013$1.35M / Venture0
Aug, 2011$5M / Debt Financing0
Jan, 2011$640k / Venture0
Nov, 2010$250k / Venture0
Sep, 2010$500k / Venture0

Current Team (2)

Update

News (6)

Update
DateNews
Jan 31, 2014SEC - SEC FORM D
Jan 20, 2014SEC - SEC FORM D
Nov 29, 2013SEC - SEC FORM D
Oct 31, 2013Yahoo Finance - Lion Biotechnologies acquired Genesis Biopharma
Oct 7, 2013SEC - SEC FORM D
Jun 13, 2013SEC - SEC FORM D

Offices/Locations (1)

Update
  • Office

    10960 Wilshire Boulevard

    Suite 1050

    Los Angeles, CA 90024

    USA

Past Team (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos